论文部分内容阅读
Controlled release of peptides by plasma albumin is a successful strategy to extend half-life and improve their therapeutic effects.The short plasma half-life of thymopentin(TP5)has dramatically limited its clinical application for immunodeficiency diseases.Herein,a TP5 derivative was prepared by conjugating myristic acid at the C-terminal(TP5-MA).